- Home
- MMD vs TVRD Comparison
MMD vs TVRD Comparison
Compare MMD & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMD
- TVRD
- Stock Information
- Founded
- MMD 2012
- TVRD 2017
- Country
- MMD United States
- TVRD United States
- Employees
- MMD N/A
- TVRD N/A
- Industry
- MMD Investment Managers
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- MMD Finance
- TVRD Health Care
- Exchange
- MMD Nasdaq
- TVRD Nasdaq
- Market Cap
- MMD 274.9M
- TVRD 246.5M
- IPO Year
- MMD N/A
- TVRD N/A
- Fundamental
- Price
- MMD $15.41
- TVRD $33.88
- Analyst Decision
- MMD
- TVRD Strong Buy
- Analyst Count
- MMD 0
- TVRD 5
- Target Price
- MMD N/A
- TVRD $59.20
- AVG Volume (30 Days)
- MMD 74.7K
- TVRD 21.2K
- Earning Date
- MMD 01-01-0001
- TVRD 08-14-2025
- Dividend Yield
- MMD 4.88%
- TVRD N/A
- EPS Growth
- MMD N/A
- TVRD N/A
- EPS
- MMD N/A
- TVRD N/A
- Revenue
- MMD N/A
- TVRD N/A
- Revenue This Year
- MMD N/A
- TVRD N/A
- Revenue Next Year
- MMD N/A
- TVRD N/A
- P/E Ratio
- MMD N/A
- TVRD N/A
- Revenue Growth
- MMD N/A
- TVRD N/A
- 52 Week Low
- MMD $14.30
- TVRD $8.13
- 52 Week High
- MMD $17.67
- TVRD $36.71
- Technical
- Relative Strength Index (RSI)
- MMD 79.15
- TVRD 66.16
- Support Level
- MMD $14.53
- TVRD $29.33
- Resistance Level
- MMD $14.66
- TVRD $31.88
- Average True Range (ATR)
- MMD 0.13
- TVRD 2.09
- MACD
- MMD 0.09
- TVRD 0.49
- Stochastic Oscillator
- MMD 93.00
- TVRD 69.21
About MMD MainStay MacKay DefinedTerm Municipal Opportunities Fund
NYLI MacKay DefinedTerm Muni Opportunities Fund is a USA-based diversified closed-end management investment company. The fund's investment objective is to seek current income exempt from regular U.S. Federal income taxes as well as total return. The company predominantly invests in municipal bonds, the interest on which is, in the opinion of bond counsel to the issuers, generally excludable from gross income for regular U.S. Federal income tax purposes.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.